Global Markets for Enzyme Inhibitors

Report Highlight

• The global market for enzyme inhibitors was valued at $104.4 billion in 2010 and reached nearly $104.6 billion in 2011. This market is expected to rise at a compound annual growth rate (CAGR) of 4% and reach nearly $127.4 billion by 2016.
• The U.S. market for enzyme inhibitors was nearly $46.8 billion in 2010 and $45 billion in 2011. This market is growing at a CAGR of 1.1% and is expected to reach $47.5 billion by 2016.
• The European market for enzyme inhibitors was $32 billion in 2010, which rose to about $32.4 billion in 2011. This sector is expected to rise at a CAGR of 3.6% and reach nearly $38.7 billion by 2016

REPORT SCOPE

INTRODUCTION

STUDY GOALS AND OBJECTIVES

The overall goal of this study is to provide a comprehensive understanding of the current and future characteristics of the global market for enzyme inhibitors.

This report explores present and future strategies within the market for enzyme inhibitors, which includes proton pump inhibitors (PPIs), protease inhibitors, reverse transcriptase inhibitors, kinase inhibitors, statins, aromatase inhibitors, phosphodiesterase type 5 (PDE5) inhibitors, neuraminidase inhibitors, and angiotensin-converting enzyme (ACE) inhibitors.  The improvements in the market and the setbacks and needs of the market are discussed in this report.  The comparisons, usage, and advantages and disadvantages of different types of enzyme inhibitors are also discussed in this report.

A detailed analysis of the enzyme inhibitors industry structure has been conducted.  Revenues are broken down by region.  Sales figures are estimated for the five-year forecast period of this report, from 2011 to 2016.

Applications for enzyme inhibitors are also discussed in the report, with emphasis on the usage of the inhibitors in therapeutic categories and various disease sectors.  The report also covers significant patents and their allotments in each category.

REASONS FOR DOING THE STUDY

Extensive research in the field of enzyme inhibitors has revealed their target-specific functionality in being able to provide therapeutic treatments for various chronic diseases.  Modern industries have now begun to explore the advantages of enzyme inhibitors in their productions and processes.  This has led to steady market growth for enzyme inhibitors.

Research and development (R&D) spending, along with increasing competition, patent expirations and new technologies, is directing this to a new level.  Although, due to patent expirations, the overall revenue for the market has decreased slightly from 2009 to 2011, new advancements, new product launches and the changing lifestyle will cause the market to grow in the foreseeable future.  This study looks at almost all the systems affected by these factors.

Acquisition strategies and collaborations by companies are also covered in this report.  This study also discusses the strengths and weaknesses of each type/technology in light of the new technologies, growing competition and changing customer needs.

CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE

This report provides invaluable information to manufacturers and users of PPIs, protease inhibitors, reverse transcriptase inhibitors, kinase inhibitors, statins, aromatase inhibitors, PDE5 inhibitors, neuraminidase inhibitors, and ACE inhibitors.  Pharmaceutical and biotechnology companies, research institutes, and physicians will find this study to be of interest.

SCOPE OF REPORT

The scope of this study encompasses enzyme inhibitors in the pharmaceutical and biotechnology industry.  BCC Research analyzes each market and its applications, regulatory environment, technology involved, market projections and market share.  Technological issues include the latest trends and developments.  Emerging markets for enzyme inhibitors include countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia and New Zealand.

METHODOLOGY AND INFORMATION SOURCES

BCC conducted a comprehensive literature search, which included technical newsletters and journals.  The data were collected through interviews and correspondence with technical experts manufacturing enzyme inhibitors.  Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.

Many companies within the industry were surveyed to obtain data for this study.  Included were manufacturers and end users of enzyme inhibitors in therapeutic categories and various disease sectors industries.  The data were carefully collected from various industry sources.  BCC spoke with officials within the industry and consulted newsletters; company and product literature; and a host of technical articles, journals, indexes and abstracts.  Exhaustive investigations of databases by key terminology were completed.  In addition, the data were compiled from current financial, trade and government sources.

ANALYST CREDENTIALS

The study has been carried out by a team of professionals in the biotechnology industry.  The project manager for this project is Shalini S. Dewan, who holds a master’s degree in pharmaceutical chemistry and has more than 14 years of industry experience.  Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid.  Dewan was awarded a Gold Medal by the prime minister of India for her work and has worked with top companies in India and in the U.S.  Some of her other reports with BCC are Reagents for Chromatography; Spectroscopy, An Enduring Market; Advanced Drug Delivery Systems: Technologies and Global Markets; Orthopedic Drugs, Implants and Devices; Medical Imaging Reagents and Analysis Equipment; Pharmaceutical Regulatory Industry; The Dynamic Media, Sera and Reagent Market in Biotechnology; Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets; Chiral Technology: Global Markets; Autacoids and Related Drugs: Technologies and Global Markets; Contraceptives: Technologies and Global Markets; Liver Disease Treatments: The Global Market; Hormone Replacement Therapies and Other Hormone Therapies: Global Markets; Cardiovascular Medicine: Diagnostics, Drugs and Devices; and Cancer Therapies: Technologies and Global Markets.

The lead consultant for this project is Dr. Kapil A. Setia, who has a doctorate in life sciences.  She has a number of research publications in her credit, including her thesis on “Studies on Phenotypic Variation, Clonal Propagation and Phyto-chemistry of Tinospora cordifolia (Willd.),” which was given an award of excellence.

BCC ON-LINE SERVICES

BCC Research offers an online information retrieval service.  Its home page, located at www.bccresearch.com, enables readers to:

• Examine the complete BCC Research catalog of market research reports and place direct orders.
• Subscribe to any of BCC Research’s many industry newsletters.
• Read announcements of recently published reports and newly launched newsletters.
• Register for its well-known conferences.
• Request additional information on any BCC research product.
• Take advantage of special offers.

DISCLAIMER

The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature.  This information does not constitute managerial, legal or accounting advice, nor should it serve as a corporate policy guide, laboratory manual or an endorsement of any product, as much of the information is of a speculative in nature.  The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or from its use.

Table Of contents

INTRODUCTION - Complimentary
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY
CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE
SCOPE OF REPORT
METHODOLOGY AND INFORMATION SOURCES
ANALYST CREDENTIALS
RELATED REPORTS
BCC ON-LINE SERVICES
DISCLAIMER

SUMMARY
Table Summary : GLOBAL REVENUE OF ENZYME INHIBITORS MARKET, THROUGH 2016
Figure Summary : GLOBAL REVENUE OF ENZYME INHIBITORS MARKET, 2009-2016

OVERVIEW
DEFINITIONS
STRUCTURE OF ENZYMES
ACTIVATION ENERGY
SPECIFICITY
ENZYME SUBSTRATE INTERACTION
CONDITIONS OF ENZYME ACTION
CLASSIFICATION OF ENZYMES
REAL-LIFE APPLICATIONS OF ENZYMES
NEED FOR ENZYMES IN HUMAN BODY
WHAT ARE ENZYME INHIBITORS
WHY ENZYME INHIBITION
USE OF ENZYME INHIBITORS
MECHANISM OF ENZYME INHIBITION
TYPES OF ENZYME INHIBITORS
CLASSIFICATION OF ENZYME INHIBITORS

REGULATORY ASPECTS
Table 5 : NEW DRUG APPROVALS FOR ENZYME INHIBITORS, 2008–2011
Table 6 : NEW DRUG APPLICATIONS FOR ENZYME INHIBITORS
Table 7 : SAFETY ALERTS FOR ENZYME INHIBITORS, 2008–2011

MARKET LEADERS AND THEIR PRODUCTS FOR ENZYME INHIBITORS
Table 8 : LEADING MANUFACTURERS/SUPPLIERS OF PROTON PUMP INHIBITORS
Table 9 : LEADING MANUFACTURERS/SUPPLIERS OF PROTEASE INHIBITORS
Table 10 : LEADING MANUFACTURERS/SUPPLIERS OF KINASE INHIBITORS
Table 11 : LEADING MANUFACTURERS/SUPPLIERS OF STATINS
Table 12 : LEADING MANUFACTURERS/SUPPLIERS OF AROMATASE INHIBITORS
Table 13 : LEADING MANUFACTURERS/SUPPLIERS OF REVERSE TRANSCRIPTASE INHIBITORS
Table 14 : LEADING MANUFACTURERS/SUPPLIERS OF PED5 INHIBITORS
Table 15 : LEADING MANUFACTURERS/SUPPLIERS OF NEURAMINIDASE INHIBITORS
Table 16 : LEADING MANUFACTURERS/SUPPLIERS OF ACE INHIBITORS

NEW DEVELOPMENTS
NEW DRUGS IN CLINICAL TRIALS
Table 27 : NEW ENZYME INHIBITORS IN CLINICAL TRIALS

GLOBAL MARKETS
MARKET ANALYSIS
MARKET SHARES
MARKET BY APPLICATIONS
Table 28 : GLOBAL MARKET FOR ENZYME INHIBITORS, THROUGH 2016
Figure 1 : GLOBAL MARKET FOR ENZYME INHIBITORS, 2009-2016

MARKETS IN THE UNITED STATES
MARKET ANALYSIS
MARKET SHARES OF INDUSTRY LEADERS IN THE UNITED STATES
MARKET BY APPLICATIONS
Table 56 : U.S. MARKET FOR ENZYME INHIBITORS, THROUGH 2016
Figure 29 : U.S. MARKET FOR ENZYME INHIBITORS, 2009-2016

MARKETS IN EUROPE
MARKET ANALYSIS
MARKET SHARES OF INDUSTRY LEADERS IN EUROPE
MARKET BY APPLICATIONS
Table 83 : EUROPEAN MARKET FOR ENZYME INHIBITORS, THROUGH 2016
Figure 56 : EUROPEAN MARKET FOR ENZYME INHIBITORS, 2009-2016

EMERGING MARKETS
MARKET ANALYSIS
MARKET SHARES OF INDUSTRY LEADERS IN EMERGING MARKETS
MARKET BY APPLICATIONS
Table 110 : EMERGING MARKETS FOR ENZYME INHIBITORS, THROUGH 2016
Figure 83 : EMERGING MARKET FOR ENZYME INHIBITORS, 2009-2016

PATENT ANALYSIS
PATENTS BY YEAR
PATENTS BY TYPE
PATENTS BY COMPANY
PATENTS BY COUNTRY
PATENTS BY ASSIGNEE
Table 137 : NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2008–2012
Figure 110 : NUMBER OF PATENTS BY YEAR, 2008–2012
Figure 111 : NUMBER OF PATENTS BY YEAR, 2008–2012

CURRENT SITUATION
MARKET CONDITIONS
TRENDS AND ISSUES IN ENZYME INHIBITORS MARKET

COMPANY PROFILES
ABBOTT LABORATORIES
AMGEN INC.
ASTRAZENECA PLC
AUROBINDO PHARMA
BAYER HEALTHCARE PHARMACEUTICALS
BOEHRINGER INGELHEIM GMBH
BRISTOL-MYERS SQUIBB
CIPLA LTD.
DR. REDDY’S LABORATORIES LTD.
EISAI INC.
ELI LILLY & CO.
ENDO PHARMACEUTICALS
GILEAD SCIENCES INC.
GLAXOSMITHKLINE PLC
GLENMARK GENERICS LTD.
HETERO DRUGS LTD.
HOFFMAN-LA ROCHE LTD.
INCYTE CORP.
JOHNSON & JOHNSON
LUPIN PHARMACEUTICALS INC.
MERCK & CO. INC.
MERCK SERONO SA
MYLAN LABORATORIES INC.
MYLAN LABORATORIES LTD.
NOVARTIS AG
OSI PHARMACEUTICALS LLC
PAR PHARMACEUTICAL COMPANIES INC.
PFIZER INC.
RANBAXY LABORATORIES LTD.
ROXANE LABORATORIES LTD.
SANDOZ
SANOFI-AVENTIS
SANTARUS INC.
SUN PHARMACEUTICALS
TAKEDA PHARMACEUTICAL CO. LTD.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
VERTEX PHARMACEUTICALS
VIIV HEALTHCARE
WATSON PHARMACEUTICALS INC.

APPENDIX—ABBREVIATIONS

List of Tables

Table : GLOBAL REVENUE OF ENZYME INHIBITORS MARKET, THROUGH 2016
Table 1 : CLASSIFICATION OF ENZYME INHIBITORS
Table 2 : HISTORY OF DEVELOPMENT OF STATINS
Table 3 : HISTORY OF DISCOVERY OF PROTEASE INHIBITORS
Table 4 : DEVELOPMENT OF ACE INHIBITORS
Table 5 : NEW DRUG APPROVALS FOR ENZYME INHIBITORS, 2008–2011
Table 6 : NEW DRUG APPLICATIONS FOR ENZYME INHIBITORS
Table 7 : SAFETY ALERTS FOR ENZYME INHIBITORS, 2008–2011
Table 8 : LEADING MANUFACTURERS/SUPPLIERS OF PROTON PUMP INHIBITORS
Table 9 : LEADING MANUFACTURERS/SUPPLIERS OF PROTEASE INHIBITORS
Table 10 : LEADING MANUFACTURERS/SUPPLIERS OF KINASE INHIBITORS
Table 11 : LEADING MANUFACTURERS/SUPPLIERS OF STATINS
Table 12 : LEADING MANUFACTURERS/SUPPLIERS OF AROMATASE INHIBITORS
Table 13 : LEADING MANUFACTURERS/SUPPLIERS OF REVERSE TRANSCRIPTASE INHIBITORS
Table 14 : LEADING MANUFACTURERS/SUPPLIERS OF PED5 INHIBITORS
Table 15 : LEADING MANUFACTURERS/SUPPLIERS OF NEURAMINIDASE INHIBITORS
Table 16 : LEADING MANUFACTURERS/SUPPLIERS OF ACE INHIBITORS
Table 17 : CLINICAL TRIALS ENZYME INHIBITORS
Table 18 : CLINICAL TRIALS OF STATINS
Table 19 : CLINICAL TRIALS FOR AROMATASE INHIBITORS
Table 20 : CLINICAL TRIALS FOR REVERSE TRANSCRIPTASE INHIBITORS
Table 21 : CLINICAL TRIALS FOR PROTEIN KINASE INHIBITORS
Table 22 : CLINICAL TRIALS FOR PDE5 INHIBITORS
Table 23 : CLINICAL TRIALS FOR PDE4 INHIBITORS
Table 24 : CLINICAL TRIALS FOR PROTEASE INHIBITORS
Table 25 : CLINICAL TRIALS FOR ACE INHIBITORS
Table 26 : CLINICAL TRIALS FOR PROTON PUMP INHIBITORS
Table 27 : NEW ENZYME INHIBITORS IN CLINICAL TRIALS
Table 28 : GLOBAL MARKET FOR ENZYME INHIBITORS, THROUGH 2016
Table 29 : GLOBAL MARKET FOR PROTON PUMP INHIBITORS, THROUGH 2016
Table 30 : GLOBAL MARKET FOR PROTEASE INHIBITORS, THROUGH 2016
Table 31 : GLOBAL MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, THROUGH 2016
Table 32 : GLOBAL MARKET FOR KINASE INHIBITORS, THROUGH 2016
Table 33 : GLOBAL MARKET FOR STATINS, THROUGH 2016
Table 34 : GLOBAL MARKET FOR AROMATASE INHIBITORS, THROUGH 2016
Table 35 : GLOBAL MARKET FOR PDE5 INHIBITORS, THROUGH 2016
Table 36 : GLOBAL MARKET FOR NEURAMINIDASE INHIBITORS, THROUGH 2016
Table 37 : GLOBAL MARKET FOR ACE INHIBITORS, THROUGH 2016
Table 38 : PROTON PUMP INHIBITOR MARKET SHARES BY REGION, 2010
Table 39 : PROTEASE INHIBITOR MARKET SHARES BY REGION, 2010
Table 40 : REVERSE TRANSCRIPTASE INHIBITOR MARKET SHARES BY REGION, 2010
Table 41 : KINASE INHIBITOR MARKET SHARES BY REGION, 2010
Table 42 : STATINS INHIBITOR MARKET SHARES BY REGION, 2010
Table 43 : AROMATASE INHIBITOR MARKET SHARES BY REGION, 2010
Table 44 : PDE5 INHIBITOR MARKET SHARES BY REGION, 2010
Table 45 : NEURAMINIDASE INHIBITOR MARKET SHARES BY REGION, 2010
Table 46 : ACE INHIBITOR MARKET SHARES BY REGION, 2010
Table 47 : GLOBAL ENZYME INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/ DISEASE SECTORS, THROUGH 2016
Table 48 : GLOBAL MARKET FOR ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE, THROUGH 2016
Table 49 : GLOBAL MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE, THROUGH 2016
Table 50 : GLOBAL MARKET OF ENZYME INHIBITORS IN HIV/AIDS, THROUGH 2016
Table 51 : GLOBAL MARKET OF ENZYME INHIBITORS IN HEPATITIS, THROUGH 2016
Table 52 : GLOBAL MARKET OF ENZYME INHIBITORS IN VARIOUS CANCERS, THROUGH 2016
Table 53 : GLOBAL MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION, THROUGH 2016
Table 54 : GLOBAL MARKET OF ENZYME INHIBITORS IN OTHER SECTORS, THROUGH 2016
Table 55 : GLOBAL MARKET SHARE OF ENZYME INHIBITORS BY APPLICATION, 2010
Table 56 : U.S. MARKET FOR ENZYME INHIBITORS, THROUGH 2016
Table 57 : U.S. MARKET FOR PROTON PUMP INHIBITORS, THROUGH 2016
Table 58 : U.S. MARKET FOR PROTEASE INHIBITORS, THROUGH 2016
Table 59 : U.S. MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, THROUGH 2016
Table 60 : U.S. MARKET FOR KINASE INHIBITORS, THROUGH 2016
Table 61 : U.S. MARKET FOR STATINS, THROUGH 2016
Table 62 : U.S. MARKET FOR AROMATASE INHIBITORS, THROUGH 2016
Table 63 : U.S. MARKET FOR PDE5 INHIBITORS, THROUGH 2016
Table 64 : U.S. MARKET FOR NEURAMINIDASE INHIBITORS, THROUGH 2016
Table 65 : U.S. MARKET FOR ACE INHIBITORS, THROUGH 2016
Table 66 : U.S. MARKET SHARES OF PROTON PUMP INHIBITOR MANUFACTURERS, 2010
Table 67 : U.S. MARKET SHARES OF PROTEASE INHIBITOR MANUFACTURERS, 2010
Table 68 : U.S. MARKET SHARES OF KINASE INHIBITOR MANUFACTURERS, 2010
Table 69 : U.S. MARKET SHARES OF STATINS MANUFACTURERS, 2010
Table 70 : U.S. MARKET SHARES OF AROMATASE INHIBITOR MANUFACTURERS, 2010
Table 71 : U.S. MARKET SHARES OF REVERSE TRANSCRIPTASE INHIBITOR MANUFACTURERS, 2010
Table 72 : U.S. MARKET SHARES OF PDE5 INHIBITOR MANUFACTURERS, 2010
Table 73 : U.S. MARKET SHARES OF NEURAMINIDASE INHIBITOR MANUFACTURERS, 2010
Table 74 : U.S. MARKET SHARES OF ACE INHIBITOR MANUFACTURERS, 2010
Table 75 : U.S. ENZYME INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/DISEASE SECTORS, THROUGH 2016
Table 76 : U.S. MARKET OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE, THROUGH 2016
Table 77 : U.S. MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE, THROUGH 2016
Table 78 : U.S. MARKET OF ENZYME INHIBITORS IN HIV/AIDS, THROUGH 2016
Table 79 : U.S. MARKET OF ENZYME INHIBITORS IN HEPATITIS, THROUGH 2016
Table 80 : U.S. MARKET OF ENZYME INHIBITORS IN VARIOUS CANCER, THROUGH 2016
Table 81 : U.S. MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION, THROUGH 2016
Table 82 : U.S. MARKET OF ENZYME INHIBITORS IN OTHER SECTORS, THROUGH 2016
Table 83 : EUROPEAN MARKET FOR ENZYME INHIBITORS, THROUGH 2016
Table 84 : EUROPEAN MARKET FOR PROTON PUMP INHIBITORS, THROUGH 2016
Table 85 : EUROPEAN MARKET FOR PROTEASE INHIBITORS, THROUGH 2016
Table 86 : EUROPEAN MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, THROUGH 2016
Table 87 : EUROPEAN MARKET FOR KINASE INHIBITORS, THROUGH 2016
Table 88 : EUROPEAN MARKET FOR STATINS, THROUGH 2016
Table 89 : EUROPEAN MARKET FOR AROMATASE INHIBITORS, THROUGH 2016
Table 90 : EUROPEAN MARKET FOR PDE5 INHIBITORS, THROUGH 2016
Table 91 : EUROPEAN MARKET FOR NEURAMINIDASE INHIBITORS, THROUGH 2016
Table 92 : EUROPEAN MARKET FOR ACE INHIBITORS, THROUGH 2016
Table 93 : EUROPEAN MARKET SHARES OF PROTON PUMP INHIBITOR MANUFACTURERS, 2010
Table 94 : EUROPEAN MARKET SHARES OF PROTEASE INHIBITOR MANUFACTURERS, 2010
Table 95 : EUROPEAN MARKET SHARES OF KINASE INHIBITOR MANUFACTURERS, 2010
Table 96 : EUROPEAN MARKET SHARES OF STATINS MANUFACTURERS, 2010
Table 97 : EUROPEAN MARKET SHARES OF AROMATASE INHIBITOR MANUFACTURERS, 2010
Table 98 : EUROPEAN MARKET SHARES OF REVERSE TRANSCRIPTASE INHIBITOR MANUFACTURERS, 2010
Table 99 : EUROPEAN MARKET SHARES OF PDE5 INHIBITOR MANUFACTURERS, 2010
Table 100 : EUROPEAN MARKET SHARES OF NEURAMINIDASE INHIBITOR MANUFACTURERS, 2010
Table 101 : EUROPEAN MARKET SHARES OF ACE INHIBITOR MANUFACTURERS, 2010
Table 102 : EUROPEAN ENZYME INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/DISEASE SECTORS, THROUGH 2016
Table 103 : EUROPEAN MARKET OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE, THROUGH 2016
Table 104 : EUROPEAN MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE, THROUGH 2016
Table 105 : EUROPEAN MARKET OF ENZYME INHIBITORS IN HIV/AIDS, THROUGH 2016
Table 106 : EUROPEAN MARKET OF ENZYME INHIBITORS IN VARIOUS CANCERS, THROUGH 2016
Table 107 : EUROPEAN MARKET OF ENZYME INHIBITORS IN HEPATITIS, THROUGH 2016
Table 108 : EUROPEAN MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION, THROUGH 2016
Table 109 : EUROPEAN MARKET OF ENZYME INHIBITORS IN OTHER DISEASES, THROUGH 2016
Table 110 : EMERGING MARKETS FOR ENZYME INHIBITORS, THROUGH 2016
Table 111 : EMERGING MARKETS FOR PROTON PUMP INHIBITORS, THROUGH 2016
Table 112 : EMERGING MARKETS FOR PROTEASE INHIBITORS, THROUGH 2016
Table 113 : EMERGING MARKETS FOR REVERSE TRANSCRIPTASE INHIBITORS, THROUGH 2016
Table 114 : EMERGING MARKETS FOR KINASE INHIBITORS, THROUGH 2016
Table 115 : EMERGING MARKETS FOR STATINS, THROUGH 2016
Table 116 : EMERGING MARKETS FOR AROMATASE INHIBITORS, THROUGH 2016
Table 117 : EMERGING MARKETS FOR PDE5 INHIBITORS, THROUGH 2016
Table 118 : EMERGING MARKETS FOR NEURAMINIDASE INHIBITORS, THROUGH 2016
Table 119 : EMERGING MARKETS FOR ACE INHIBITORS, THROUGH 2016
Table 120 : EMERGING MARKET SHARES OF PROTON PUMP INHIBITOR MANUFACTURERS, 2010
Table 121 : EMERGING MARKET SHARES OF PROTEASE INHIBITOR MANUFACTURERS, 2010
Table 122 : EMERGING MARKET SHARES OF KINASE INHIBITOR MANUFACTURERS, 2010
Table 123 : EMERGING MARKET SHARES OF STATINS MANUFACTURERS, 2010
Table 124 : EMERGING MARKET SHARES OF AROMATASE INHIBITOR, 2010
Table 125 : EMERGING MARKET SHARES OF REVERSE TRANSCRIPTASE INHIBITOR MANUFACTURERS, 2010
Table 126 : EMERGING MARKET SHARES OF PDE5 INHIBITOR MANUFACTURERS, 2010
Table 127 : EMERGING MARKET SHARES OF NEURAMINIDASE INHIBITOR MANUFACTURERS, 2010
Table 128 : EMERGING MARKET SHARES OF ACE INHIBITOR MANUFACTURERS, 2010
Table 129 : EMERGING MARKETS IN ENZYME INHIBITORS BY THERAPEUTIC CATEGORIES/DISEASE SECTORS, THROUGH 2016
Table 130 : EMERGING MARKETS OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASES, THROUGH 2016
Table 131 : EMERGING MARKETS OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASES, THROUGH 2016
Table 132 : EMERGING MARKETS OF ENZYME INHIBITORS IN HIV/AIDS, THROUGH 2016
Table 133 : EMERGING MARKETS OF ENZYME INHIBITORS IN HEPATITIS, THROUGH 2016
Table 134 : EMERGING MARKETS OF ENZYME INHIBITORS IN VARIOUS CANCERS, THROUGH 2016
Table 135 : EMERGING MARKETS OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION, THROUGH 2016
Table 136 : EMERGING MARKETS OF ENZYME INHIBITORS IN OTHER DISEASES, THROUGH 2016
Table 137 : NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2008–2012
Table 138 : PATENTS BY TYPE FOR ENZYME INHIBITORS, 2008–2012
Table 139 : NUMBER OF U.S. PATENTS BY COMPANY FOR ENZYME INHIBITORS, 2008–2012
Table 140 : TOTAL NUMBER OF U.S. PATENTS BY COUNTRY FOR ENZYME INHIBITORS, 2008–2012
Table 141 : PATENT SHARES BY COUNTRY FOR INDUSTRIAL ENZYMES, 2008–2012
Table 142 : PATENTS BY TYPE FOR INDUSTRIAL ENZYMES, 2008–2012

List of Figures

Figure : GLOBAL REVENUE OF ENZYME INHIBITORS MARKET, 2009-2016
Figure 1 : GLOBAL MARKET FOR ENZYME INHIBITORS, 2009-2016
Figure 2 : GLOBAL MARKET FOR PROTON PUMP INHIBITORS, 2009-2016
Figure 3 : GLOBAL MARKET FOR PROTEASE INHIBITORS, 2009-2016
Figure 4 : GLOBAL MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, 2009-2016
Figure 5 : GLOBAL MARKET FOR KINASE INHIBITORS, 2009-2016
Figure 6 : GLOBAL MARKET FOR STATINS, 2009-2016
Figure 7 : GLOBAL MARKET FOR AROMATASE INHIBITORS, 2009-2016
Figure 8 : GLOBAL MARKET FOR PDE5 INHIBITORS, 2009-2016
Figure 9 : GLOBAL MARKET FOR NEURAMINIDASE INHIBITORS, 2009-2016
Figure 10 : GLOBAL MARKET FOR ACE INHIBITORS, 2009-2016
Figure 11 : PROTON PUMP INHIBITOR MARKET SHARES BY REGION, 2010
Figure 12 : PROTEASE INHIBITOR MARKET SHARES BY REGION, 2010
Figure 13 : REVERSE TRANSCRIPTASE INHIBITOR MARKET SHARES BY REGION, 2010
Figure 14 : KINASE INHIBITOR MARKET SHARES BY REGION, 2010
Figure 15 : STATINS INHIBITOR MARKET SHARES BY REGION, 2010
Figure 16 : AROMATASE INHIBITOR MARKET SHARES BY REGION, 2010
Figure 17 : PDE5 INHIBITOR MARKET SHARES BY REGION, 2010
Figure 18 : NEURAMINIDASE INHIBITOR MARKET SHARES BY REGION, 2010
Figure 19 : ACE INHIBITOR MARKET SHARES BY REGION, 2010
Figure 20 : GLOBAL ENZYME INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/ DISEASE SECTORS, 2009-2016
Figure 21 : GLOBAL MARKET OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE, 2009-2016
Figure 22 : GLOBAL MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE, 2009-2016
Figure 23 : GLOBAL MARKET OF ENZYME INHIBITORS IN HIV/AIDS, 2009-2016
Figure 24 : GLOBAL MARKET OF ENZYME INHIBITORS IN HEPATITIS, 2009-2016
Figure 25 : GLOBAL MARKET OF ENZYME INHIBITORS IN VARIOUS CANCERS, 2009-2016
Figure 26 : GLOBAL MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION, 2009-2016
Figure 27 : GLOBAL MARKET OF ENZYME INHIBITORS IN OTHER SECTORS, 2009-2016
Figure 28 : GLOBAL MARKET SHARE OF TECHNICAL ENZYMES, 2010
Figure 29 : U.S. MARKET FOR ENZYME INHIBITORS, 2009-2016
Figure 30 : U.S. MARKET FOR PROTON PUMP INHIBITORS, 2009-2016
Figure 31 : U.S. MARKET FOR PROTEASE INHIBITORS, 2009-2016
Figure 32 : U.S. MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, 2009-2016
Figure 33 : U.S. MARKET FOR KINASE INHIBITORS, 2009-2016
Figure 34 : U.S. MARKET FOR STATINS, 2009-2016
Figure 35 : U.S. MARKET FOR AROMATASE INHIBITORS, 2009-2016
Figure 36 : U.S. MARKET FOR PDE5 INHIBITORS, 2009-2016
Figure 37 : U.S. MARKET FOR NEURAMINIDASE INHIBITORS, 2009-2016
Figure 38 : U.S. MARKET FOR ACE INHIBITORS, 2009-2016
Figure 39 : U.S. MARKET SHARES OF PROTON PUMP INHIBITOR MANUFACTURERS, 2010
Figure 40 : U.S. MARKET SHARES OF PROTEASE INHIBITORS MANUFACTURERS, 2010
Figure 41 : U.S. MARKET SHARES OF KINASE INHIBITORS MANUFACTURERS, 2010
Figure 42 : U.S. MARKET SHARES OF STATINS MANUFACTURERS, 2010
Figure 43 : U.S. MARKET SHARES OF AROMATASE INHIBITOR MANUFACTURERS, 2010
Figure 44 : U.S. MARKET SHARES OF REVERSE TRANSCRIPTASE INHIBITOR MANUFACTURERS, 2010
Figure 45 : U.S. MARKET SHARES OF PDE5 MANUFACTURERS, 2010
Figure 46 : U.S. MARKET SHARES OF NEURAMINIDASE MANUFACTURERS, 2010
Figure 47 : U.S. MARKET SHARES OF ACE MANUFACTURERS, 2010
Figure 48 : U.S. MARKET INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/DISEASE SECTORS, 2009-2016
Figure 49 : U.S. MARKET OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE, 2009-2016
Figure 50 : U.S. MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE, 2009-2016
Figure 51 : U.S. MARKET OF ENZYME INHIBITORS IN HIV/AIDS, 2009-2016
Figure 52 : U.S. MARKET OF ENZYME INHIBITORS IN HEPATITIS, 2009-2016
Figure 53 : U.S. MARKET OF ENZYME INHIBITORS IN VARIOUS CANCER, 2009-2016
Figure 54 : U.S. MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION, 2009-2016
Figure 55 : U.S. MARKET OF ENZYME INHIBITORS IN OTHER SECTORS, 2009-2016
Figure 56 : EUROPEAN MARKET FOR ENZYME INHIBITORS, 2009-2016
Figure 57 : EUROPEAN MARKET FOR PROTON PUMP INHIBITORS, 2009-2016
Figure 58 : EUROPEAN MARKET FOR PROTEASE INHIBITORS, 2009-2016
Figure 59 : EUROPEAN MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, 2009-2016
Figure 60 : EUROPEAN MARKET FOR KINASE INHIBITORS, 2009-2016
Figure 61 : EUROPEAN MARKET FOR STATINS, 2009-2016
Figure 62 : EUROPEAN MARKET FOR AROMATASE INHIBITORS, 2009-2016
Figure 63 : EUROPEAN MARKET FOR PDE5 INHIBITORS, THROUGH 2016
Figure 64 : EUROPEAN MARKET FOR NEURAMINIDASE INHIBITORS, 2009-2016
Figure 65 : EUROPEAN MARKET FOR ACE INHIBITORS, 2009-2016
Figure 66 : EUROPEAN MARKET SHARES OF PROTON PUMP INHIBITOR MANUFACTURERS, 2010
Figure 67 : EUROPEAN MARKET SHARES OF PROTEASE INHIBITORS MANUFACTURERS, 2010
Figure 68 : EUROPEAN MARKET SHARES OF KINASE INHIBITORS MANUFACTURERS, 2010
Figure 69 : EUROPEAN MARKET SHARES OF STATINS MANUFACTURERS, 2010
Figure 70 : EUROPEAN MARKET SHARES OF AROMATASE INHIBITOR MANUFACTURERS, 2010
Figure 71 : EUROPEAN MARKET SHARES OF REVERSE TRANSCRIPTASE MANUFACTURERS, 2010
Figure 72 : EUROPEAN MARKET SHARES OF PDE5 INHIBITOR MANUFACTURERS, 2010
Figure 73 : EUROPEAN MARKET SHARES OF NEURAMINIDASE INHIBITOR MANUFACTURERS, 2010
Figure 74 : EUROPEAN MARKET SHARES OF ACE INHIBITOR MANUFACTURERS, 2010
Figure 75 : EUROPEAN ENZYME INHIBITORS MARKET BY THERAPEUTIC CATEGORIES/DISEASE SECTORS, 2009-2016
Figure 76 : EUROPEAN MARKET OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE, 2009-2016
Figure 77 : EUROPEAN MARKET OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASE, 2009-2016
Figure 78 : EUROPEAN MARKET OF ENZYME INHIBITORS IN HIV/AIDS, 2009-2016
Figure 79 : EUROPEAN MARKET OF ENZYME INHIBITORS IN CANCER, 2009-2016
Figure 80 : EUROPEAN MARKET OF ENZYME INHIBITORS IN HEPATITIS, 2009-2016
Figure 81 : EUROPEAN MARKET OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION, 2009-2016
Figure 82 : EUROPEAN MARKET OF ENZYME INHIBITORS IN OTHER DISEASES, 2009-2016
Figure 83 : EMERGING MARKET FOR ENZYME INHIBITORS, 2009-2016
Figure 84 : EMERGING MARKETS FOR PROTON PUMP INHIBITORS, 2009-2016
Figure 85 : EMERGING MARKETS FOR PROTEASE INHIBITORS, 2009-2016
Figure 86 : EMERGING MARKETS FOR REVERSE TRANSCRIPTASE INHIBITORS, 2009-2016
Figure 87 : EMERGING MARKETS FOR KINASE INHIBITORS, 2009-2016
Figure 88 : EMERGING MARKETS FOR STATINS, 2009-2016
Figure 89 : EMERGING MARKETS FOR AROMATASE INHIBITORS, 2009-2016
Figure 90 : EMERGING MARKETS FOR PDE5 INHIBITORS, 2009-2016
Figure 91 : EMERGING MARKETS FOR NEURAMINIDASE INHIBITORS, 2009-2016
Figure 92 : EMERGING MARKETS FOR ACE INHIBITORS, 2009-2016
Figure 93 : EMERGING MARKET SHARES OF PROTON PUMP INHIBITOR MANUFACTURERS, 2010
Figure 94 : EMERGING MARKETS SHARES OF PROTEASE INHIBITORS MANUFACTURERS, 2010
Figure 95 : EMERGING MARKET SHARES OF KINASE INHIBITORS MANUACTURERS, 2010
Figure 96 : EMERGING MARKETS SHARES OF STATINS MANUFACTURERS, 2010
Figure 97 : EMERGING MARKET SHARES OF AROMATASE INHIBITOR MANUFACTURERS, 2010
Figure 98 : EMERGING MARKET SHARES OF REVERSE TRANSCRIPTASE MANUFACTURERS, 2010
Figure 99 : EMERGING MARKET SHARES OF PED5 MANUFACTURERS, 2010
Figure 100 : EMERGING MARKET SHARES OF NEURAMINIDASE MANUFACTURERS, 2010
Figure 101 : EMERGING MARKET SHARES OF ACE INHIBITOR MANUFACTURERS, 2010
Figure 102 : EMERGING MARKETS IN ENZYME INHIBITORS BY THERAPEUTIC CATEGORIES/DISEASE SECTORS
Figure 103 : EMERGING MARKETS OF ENZYME INHIBITORS IN CARDIOVASCULAR DISEASES, 2009-2016
Figure 104 : EMERGING MARKETS OF ENZYME INHIBITORS IN GASTROINTESTINAL DISEASES, 2009-2016
Figure 105 : EMERGING MARKETS OF ENZYME INHIBITORS IN HIV/AIDS, 2009-2016
Figure 106 : EMERGING MARKETS OF ENZYME INHIBITORS IN HEPATITIS, 2009-2016
Figure 107 : EMERGING MARKETS OF ENZYME INHIBITORS IN VARIOUS CANCERS, 2009-2016
Figure 108 : EMERGING MARKETS OF ENZYME INHIBITORS IN ERECTILE DYSFUNCTION, 2009-2016
Figure 109 : EMERGING MARKETS OF ENZYME INHIBITORS IN OTHER DISEASES, 2009-2016
Figure 110 : NUMBER OF PATENTS BY YEAR, 2008–2012
Figure 111 : NUMBER OF PATENTS BY YEAR, 2008–2012
Figure 112 : PATENTS BY TYPE FOR ENZYME INHIBITORS, 2008–2012
Figure 113 : TOTAL NUMBER OF U.S. PATENTS BY COUNTRY FOR ENZYME INHIBITORS, 2008–2012
Figure 114 : PATENT SHARES BY COUNTRY FOR ENZYME INHIBITORS, 2008–2012
Figure 115 : PATENTS BY ASSIGNEE FOR INDUSTRIAL ENZYMES, 2008–2012